For the latest updates on our ongoing response to COVID-19, please click here.

                        Pipeline

                        The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

                        The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

                        Pipeline

                        Viral?Diseases

                        • Biktarvy

                          HIV treatment pediatric1

                          Phase 1
                          Phase 2
                          Phase 3
                        • Capsid inhibitor (GS-6207)

                          HIV HTE2

                          Phase 1
                          Phase 2
                          Phase 3
                        • Capsid inhibitor (GS-6207)

                          HIV treatment na?ve

                          Phase 1
                          Phase 2
                          Phase 3
                        • Vesatolimod (GS-9620, TLR-7 agonist)

                          HIV cure

                          Phase 1
                          Phase 2
                          Phase 3
                        • Elipovimab (GS-9722, bNab)

                          HIV cure

                          Phase 1
                          Phase 2
                          Phase 3
                        • Selgantolimod (GS-9688, TLR-8 agonist)

                          HBV cure

                          Phase 1
                          Phase 2
                          Phase 3
                        • PD-L1 inhibitor (GS-4224)

                          HBV cure

                          Phase 1
                          Phase 2
                          Phase 3

                        1 Biktarvy HIV treatment pediatric label extension.

                        2 Registrational for heavily treatment-experienced (HTE) patients.

                        Inflammatory diseases

                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Rheumatoid arthritis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Ulcerative colitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Crohn's disease

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Psoriatic arthritis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Ankylosing spondylitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Filgotinib (GS-6034, JAK-1 inhibitor)

                          Uveitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • TPL2 inhibitor (GS-4875)

                          Ulcerative colitis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-19721

                          Osteoarthritis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-05551

                          Inflammatory diseases

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-33121

                          Inflammatory diseases

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-39701

                          Inflammatory diseases

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-36671

                          Inflammatory diseases

                          Phase 1
                          Phase 2
                          Phase 3

                        1 Optionable partner program.

                        Fibrotic Diseases

                        • Cilofexor (GS-9674, FXR agonist)

                          PSC

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-16901

                          Idiopathic Pulmonary Fibrosis

                          Phase 1
                          Phase 2
                          Phase 3
                        • Cilofexor (FXR agonist)

                          NASH

                          Phase 1
                          Phase 2
                          Phase 3
                        • Firsocostat (ACC inhibitor)

                          NASH

                          Phase 1
                          Phase 2
                          Phase 3
                        • Selonsertib (ASK1 inhibitor) combinations

                          NASH

                          Phase 1
                          Phase 2
                          Phase 3
                        • Selonsertib (GS-4997, ASK1 inhibitor)

                          DKD

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-16901

                          Systemic sclerosis

                          Phase 1
                          Phase 2
                          Phase 3
                        • GLPG-12052

                          Idiopathic pulmonary fibrosis

                          Phase 1
                          Phase 2
                          Phase 3

                        1 Optioned parter program.

                        2 Optionable partner program.

                        Oncology

                        • KTE-X19

                          MCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axi-cel

                          2L DLBCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axi-cel

                          Indolent NHL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axi-cel

                          1L DLBCL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axi-cel

                          DLBCL (+rituximab or lenalidomide)

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Adult ALL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          Pediatric ALL

                          Phase 1
                          Phase 2
                          Phase 3
                        • KTE-X19

                          CLL

                          Phase 1
                          Phase 2
                          Phase 3
                        • Axi-cel

                          DLBCL (utomilumab)

                          Phase 1
                          Phase 2
                          Phase 3
                        • KITE-718 (MAGE A3/A6)

                          Solid tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • KITE-439 (HPV E7)

                          Solid tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • Oral PD-L1 inhibitor (GS-4224)

                          Solid tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • anti-CD73/TGF? TRAP (GS-1423)1

                          Solid tumor

                          Phase 1
                          Phase 2
                          Phase 3
                        • Bi-specific mAb (AGEN1223)2,3,4

                          Multiple

                          Phase 1
                          Phase 2
                          Phase 3
                        • Anti-CD137 mAb mAb (AGEN2373)3,4

                          Multiple

                          Phase 1
                          Phase 2
                          Phase 3

                        1 TME conditioning anti-CD73/TGF? TRAP bifunctional fusion protein (GS-1423).

                        2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

                        3 Exclusive option to license right from Agenus upon proof of concept data.

                        4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.

                        三级黄片